Anavex Gains Momentum as European Filing for Alzheimer’s Drug Begins

November 22, 2023

Categories: BiotechnologyTags: , , Views: 24

☀️Trending News

Anavex Life Sciences ($NASDAQ:AVXL) Corp. is a biopharmaceutical company focused on utilizing novel drug candidates to treat neurological diseases like Alzheimer’s. This week, shares of the company have gained momentum as the European Union has begun reviewing its application for an Alzheimer’s drug. The submission of the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) represents a major milestone for Anavex Life Sciences. Anavex is also in the process of filing for approval in other jurisdictions including the United States, where it has already been granted orphan drug status.

Price History

This surge in stock value was spurred by the announcement that the company had begun the process of filing for approval of their drug for Alzheimer’s treatment in Europe. The filing brings them one step closer to progressing toward their goal of providing new treatments and potential cures for Alzheimer’s and other diseases. ANAVEX LIFE SCIENCES is currently working on a number of treatments for neurological diseases and conditions and is hopeful that this filing will be the first step towards offering life-saving treatments for those suffering from such conditions. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for AVXL. More…

    Total Revenues Net Income Net Margin
    0 -51.65
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for AVXL. More…

    Operations Investing Financing
    -25.98 0 27.6
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for AVXL. More…

    Total Assets Total Liabilities Book Value Per Share
    157.81 11.06 1.82
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for AVXL are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    FCF Margin ROE ROA
    -23.0% -21.3%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    As an investor researching ANAVEX LIFE SCIENCES, I used GoodWhale’s Star Chart to analyze its fundamentals. The Star Chart classified ANAVEX LIFE SCIENCES as an ‘elephant’, which means it is a company that is rich in assets after deducting off liabilities. This type of company is likely to attract investors who are interested in long-term investments and capital appreciation. GoodWhale also provides a health score of 4/10 for ANAVEX LIFE SCIENCES, taking into account its cashflows and debt. This indicates that the company has an intermediate health score, meaning that it is likely to sustain future operations in times of crisis. However, GoodWhale’s Star Chart also showed that while ANAVEX LIFE SCIENCES is strong in asset, it is weak in dividend, growth, and profitability. This means that investing in this company is probably not the best choice for investors who are seeking to receive high returns in the short-term. More…

  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The Company’s lead drug candidate, ANAVEX 2-73, is being developed to treat Alzheimer’s disease (AD) and other CNS diseases. ANAVEX 2-73 is a small molecule that restores brain cell function and reverses the course of AD. The Company is also developing ANAVEX 3-71, which is in preclinical stage for the treatment of Parkinson’s disease and other CNS diseases. Both ANAVEX 2-73 and ANAVEX 3-71 target sigma-1 and muscarinic receptors.

    – AN2 Therapeutics Inc ($NASDAQ:ANTX)

    Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes small molecule drugs to treat serious unmet medical needs, primarily in oncology. As of December 31, 2020, the company had one marketed product, Jakafi (ruxolitinib), and two clinical-stage candidates in various stages of development. Jakafi is approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea, and patients with relapsed or refractory acute myeloid leukemia (AML).

    – Aadi Bioscience Inc ($NASDAQ:AADI)

    Aadi Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic antibodies for the treatment of cancer and other serious diseases. The company has a market cap of 262.08M as of 2022 and a Return on Equity of -72.24%. Aadi Bioscience Inc’s products are in various stages of development, with the most advanced product candidate, AB101, being evaluated in a Phase 1/2 clinical trial in patients with relapsed or refractory B-cell malignancies.


    ANAVEX Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel drug candidates for the treatment of Alzheimer’s disease and other central nervous system (CNS) diseases. Recently, the company has made an EU filing for its lead Alzheimer’s drug, which has caused its stock prices to move up the same day. This is a positive sign for potential investors, as it indicates that the company is making progress in its clinical trials.

    However, investing in early-stage companies such as ANAVEX Life Sciences comes with greater risk than investing in more established companies. Therefore, investors should conduct thorough research and consider the potential risks before investing.

    Recent Posts

    Leave a Comment